Restore Pharma Educational Series | Tampa Bay, Florida
When people hear the word "peptide," one of the first things they think about is an injection. For years, injectable medications have played an important role in peptide-based therapies because they offer a way to deliver compounds that may otherwise be broken down in the digestive system.
But does that mean every peptide must be injected to produce a biological effect?
Not necessarily.
Advances in pharmaceutical formulation have created opportunities to explore alternative routes of administration, including medications that dissolve under the tongue or against the inside of the cheek. One such option is a troche, a specially prepared dosage form designed to dissolve in the mouth.
Troches have been used in compounding pharmacy for years, particularly in hormone replacement therapy and other areas where individualized medication delivery may be beneficial.
More recently, interest in sublingual and buccal delivery has expanded into peptides, raising questions about absorption, bioavailability, convenience, and whether certain compounds can be administered without injections.
Unfortunately, there's also a considerable amount of misinformation surrounding these delivery systems.
Some online research-peptide communities suggest that peptides administered through troches are completely ineffective because the digestive system destroys them. Others claim that sublingual delivery works just as well as an injection for nearly every compound.
Neither statement accurately reflects the science.
At Restore Pharma, we believe patients deserve a better explanation. Understanding how troches work, what makes them different from traditional oral medications, and why formulation matters can help patients and healthcare providers make more informed decisions.
What Is a Troche?
A troche is a solid or semisolid medication designed to dissolve slowly in the mouth.
Depending on the formulation and prescribed instructions, a troche may be placed underneath the tongue or between the cheek and gum.
These areas contain mucosal tissue, which provides a potential pathway for certain medications to enter the bloodstream.
Unlike a traditional tablet that is swallowed immediately, a troche is designed to remain in contact with the oral tissues as it dissolves.
This creates an opportunity for medication absorption through the mucous membranes rather than relying entirely on the gastrointestinal tract.
Troches can be prepared using different pharmaceutical bases and may contain one or more active ingredients when clinically appropriate and legally permitted.
For patients, the appeal is easy to understand. Troches don't require needles, syringes, or an injection technique, and they may offer an alternative when an appropriate commercially available dosage form doesn't meet a patient's needs.
However, the effectiveness of a troche depends on much more than simply placing medication under the tongue.
The active ingredient, its chemical properties, the formulation, and the amount absorbed all play important roles.
How Does Sublingual Absorption Work?
The word sublingual means underneath the tongue.
The tissue beneath the tongue contains a network of small blood vessels, making it a useful location for delivering certain medications into systemic circulation.
When an appropriate medication dissolves under the tongue, some of its molecules may cross the mucosal barrier and enter the underlying blood vessels.
From there, the absorbed medication can reach the bloodstream without first traveling through the stomach and intestines.
This is one reason sublingual administration has been used successfully with certain established medications.
The buccal route works through a similar principle, except the medication is held against the inner cheek rather than underneath the tongue.
Although the two routes share similarities, the tissues differ in thickness, surface area, and permeability.
The choice of location can influence how a medication is absorbed.
It's also important to understand that not every molecule dissolved in the mouth will enter the bloodstream through these tissues.
Some medication may remain unabsorbed and eventually be swallowed with saliva.
That swallowed portion then enters the gastrointestinal tract, where it may undergo digestion and first-pass metabolism.
For this reason, a troche's actual absorption profile may involve both transmucosal and gastrointestinal pathways.
What Is First-Pass Metabolism?
First-pass metabolism is an important concept in pharmaceutical science.
When a medication is swallowed, it generally travels through the gastrointestinal tract before entering the portal circulation and reaching the liver.
During this process, enzymes in the intestinal wall and liver may metabolize part of the medication before it reaches systemic circulation.
For some medications, this substantially reduces the amount of active drug available to produce an effect.
Sublingual and buccal delivery can potentially reduce this initial exposure to gastrointestinal and hepatic metabolism when medication is absorbed directly through the oral mucosa.
This is one of the major reasons scientists continue to investigate these routes.
However, the benefit depends on how much of the medication actually crosses the mucosal tissue.
A compound that dissolves readily but doesn't penetrate the mucosal barrier may still be swallowed and undergo gastrointestinal metabolism.
This is why formulation science matters so much.
Are Peptides Destroyed by the Digestive System?
This is one of the most common arguments against noninjectable peptide delivery.
Peptides are chains of amino acids, and the digestive system contains enzymes that break down proteins and peptides.
Because of this, many peptides have poor oral bioavailability when swallowed in conventional formulations.
That part of the argument is scientifically valid.
But it doesn't tell the whole story.
Sublingual and buccal administration are not identical to swallowing a conventional oral medication.
These routes create an opportunity for certain compounds to cross the oral mucosa before entering the gastrointestinal tract.
Researchers have investigated transmucosal peptide delivery precisely because conventional oral administration presents significant challenges.
A scientific review published in Advanced Drug Delivery Reviews examined factors influencing buccal peptide absorption, including molecular size, hydrophilicity, membrane permeability, and enzymatic degradation.
The authors also discussed pharmaceutical strategies intended to improve absorption.
The important distinction is that peptide absorption through oral mucosa is scientifically possible, but often difficult.
The presence of digestive enzymes does not prove that every peptide troche is ineffective.
At the same time, avoiding immediate swallowing does not guarantee that a peptide will be absorbed.
Both ideas can be true.
Why Are Some Peptides More Difficult to Absorb Than Others?
Not all peptides behave the same way.
A peptide's molecular weight, amino acid sequence, electrical charge, solubility, stability, and interaction with biological membranes can all influence its absorption.
Smaller molecules may have advantages in crossing certain biological barriers, although molecular size alone doesn't determine whether absorption will occur.
Many peptides are relatively water-soluble, which can make it difficult for them to cross the lipid-rich portions of cellular membranes.
Others may be vulnerable to enzymes present in saliva or oral tissues.
Some peptides may also degrade before a meaningful amount reaches circulation.
These challenges help explain why an injectable formulation may achieve substantially different exposure than a troche containing the same active ingredient.
For example, a peptide that produces a measurable response following injection may have little systemic absorption when administered through an unoptimized oral-mucosal formulation.
Conversely, a carefully developed delivery system may improve absorption compared with a simple formulation.
The important question isn't whether all peptide troches work or fail.
It's whether a specific peptide, in a specific formulation, has demonstrated adequate absorption and meaningful biological activity through the intended route.
The Role of Pharmaceutical Formulation
One of the biggest misconceptions about troches is that every formulation is essentially the same.
In reality, the inactive ingredients used to prepare a medication can significantly influence its physical characteristics and performance.
A troche base helps determine how the dosage form dissolves, how long it remains in contact with oral tissues, and how the active ingredient is released.
Other formulation characteristics, including pH, moisture sensitivity, drug compatibility, and chemical stability, may also influence performance.
Researchers have explored specialized approaches to improving transmucosal peptide delivery, including mucoadhesive polymers, permeation enhancers, and other delivery technologies.
Mucoadhesive systems are designed to increase contact between a medication and mucosal tissue.
Permeation enhancers are investigated for their ability to influence how molecules cross biological barriers.
However, these approaches require careful evaluation because increasing permeability can also introduce tolerability and safety concerns.
Not every ingredient or delivery technology is appropriate for every medication.
This is where pharmaceutical expertise becomes especially important.
Preparing a troche involves more than selecting a flavor and adding an active ingredient. The pharmacist must consider the chemical properties of the compound, formulation compatibility, stability, patient needs, and the evidence supporting the intended route.
Even a well-prepared troche cannot overcome every biological limitation, and a formulation's theoretical advantages must be distinguished from clinically demonstrated performance.
Are Peptide Troches Actually Effective?
The most accurate answer is that effectiveness depends on the individual peptide and formulation.
Some peptides may have characteristics that make transmucosal delivery more feasible than others.
For certain compounds, laboratory studies have demonstrated movement across mucosal tissues or measurable biological responses following noninjectable administration.
Researchers continue to investigate ways to improve peptide delivery without relying on injections.
However, findings involving one peptide cannot automatically be applied to another.
A successful buccal delivery system for a particular compound does not establish that an unrelated peptide will have comparable absorption.
Similarly, evidence that a peptide produces a biological effect following injection doesn't establish that a troche containing the same peptide will produce that effect.
There are several different questions researchers must answer.
Does the peptide remain chemically stable in the formulation? Does it cross the oral mucosa? How much reaches systemic circulation? Is the absorbed amount sufficient to produce the intended biological effect? And most importantly, does the formulation improve meaningful clinical outcomes?
These questions require different types of evidence.
Laboratory permeability testing may help evaluate absorption potential. Pharmacokinetic studies can measure drug exposure. Clinical trials are needed to establish whether the medication actually benefits patients.
This is why we avoid making blanket claims about peptide troches.
The science supports investigating noninjectable peptide delivery, but it doesn't support assuming that every peptide can be effectively administered this way.
Troches and Hormone Replacement Therapy
While peptide troches remain an evolving area of research, troches have a longer history of use in compounded hormone replacement therapy.
Hormone therapy may be considered for patients experiencing clinically significant hormonal changes or conditions where replacement or supplementation is medically appropriate.
Depending on the patient and the hormone involved, treatment options may include commercially available oral medications, patches, gels, creams, vaginal preparations, injections, or other dosage forms.
Compounded troches represent another potential delivery approach in selected circumstances.
Hormones such as estradiol, progesterone, and testosterone have been incorporated into compounded sublingual or buccal formulations.
However, these hormones have different absorption characteristics, therapeutic roles, and safety considerations.
A troche containing one hormone should not be assumed to behave like a troche containing another.
Estradiol Troches
Estradiol is an estrogen hormone involved in numerous physiological functions, including reproductive health, bone maintenance, and the regulation of certain menopausal symptoms.
Sublingual estradiol administration has been investigated as a way to deliver estradiol while reducing some of the initial metabolism associated with swallowing the medication.
The route can influence the rate of absorption and the resulting hormone concentration profile.
However, compounded estradiol troches have limited clinical outcome and long-term safety data compared with FDA-approved estrogen products.
Patients also need to understand that estradiol therapy can involve important risks and that the choice of route and formulation may influence those risks.
For most patients requiring menopausal hormone therapy, FDA-approved options are preferred when suitable.
Progesterone Troches
Progesterone is another hormone commonly discussed in compounded hormone therapy.
It plays an important role in reproductive physiology and is used in certain hormone treatment regimens.
Sublingual or buccal progesterone formulations may be considered in specific individualized circumstances, but absorption and exposure can vary.
One particularly important consideration involves patients with a uterus who receive systemic estrogen therapy.
In these patients, appropriate progestogen treatment may be necessary to protect the endometrium, or uterine lining, from the effects of unopposed estrogen.
There is insufficient evidence to assume that a compounded progesterone troche provides the same endometrial protection as an established, appropriately dosed regimen.
This is an area where the specific formulation, clinical indication, and available evidence matter tremendously.
Testosterone Troches
Testosterone therapy is used in selected patients with appropriately diagnosed hormonal conditions.
Compounded testosterone troches have been explored as an alternative dosage form for certain patients who have difficulty with or cannot use other available preparations.
However, sublingual and buccal testosterone absorption can produce different hormone concentration patterns than injections, gels, or other formulations.
The choice of dosage form may influence peak concentrations, duration of exposure, and the frequency of administration.
Monitoring and individualized medical oversight are important.
For men with testosterone deficiency, FDA-approved testosterone products are generally preferred when clinically appropriate.
For women, testosterone therapy requires a separate discussion of indication, dose, monitoring, and potential adverse effects.
A compounded troche should not be assumed to be safer or more effective simply because it is customized.
Why Some Patients Prefer Troches Over Injections
One of the most obvious potential advantages of troches is convenience.
Not every patient feels comfortable with needles, and some individuals find frequent injections difficult to incorporate into their routines.
Troches eliminate the need for injection technique, sharps disposal, and the handling associated with injectable medication administration.
They may also provide an option for patients who have difficulty swallowing conventional tablets, depending on the medication and their individual circumstances.
Another potential benefit is flexibility in formulation when a patient has a legitimate clinical need that cannot be met by an appropriate commercially available medication.
However, convenience alone does not establish therapeutic equivalence.
Injections may provide more predictable systemic delivery for certain medications, while troches can produce variable absorption depending on the compound and formulation.
The goal should never be to choose a dosage form simply because it is more popular or easier to market.
The goal is to select an appropriate treatment that balances clinical evidence, patient preferences, pharmaceutical quality, and safety.
Troches vs. Injections: Is One Better?
It's tempting to frame this discussion as a competition between two delivery systems.
But in pharmacy, the best route of administration depends on the medication and the patient.
Injectable delivery can be particularly useful for compounds that have poor absorption through other routes.
Depending on the formulation, injections may provide relatively predictable systemic exposure and avoid many of the barriers associated with gastrointestinal and mucosal absorption.
Troches offer a needle-free approach and may be suitable for certain medications when adequate absorption and clinical performance have been established.
However, they may also have disadvantages involving variable absorption, saliva-related drug loss, taste, local irritation, and the possibility that some of the medication will be swallowed.
A milligram of medication in a troche should not be assumed to produce the same systemic exposure as a milligram administered by injection.
The routes are not automatically interchangeable.
For certain medications, an injection may be the better-supported option. For others, an established noninjectable dosage form may be entirely appropriate.
What matters is selecting the right formulation for the right clinical situation.
Addressing Common Myths About Peptide Troches
Myth: All peptides are destroyed unless they're injected.
Many peptides are vulnerable to digestive enzymes, and conventional oral delivery can be challenging.
However, sublingual and buccal delivery are distinct routes that may allow some drug absorption before the gastrointestinal tract is reached.
The scientific literature supports investigating transmucosal peptide delivery, although significant barriers remain.
The statement that all noninjectable peptides are ineffective is too broad.
Myth: If a troche dissolves under the tongue, the entire dose enters the bloodstream.
Dissolving is not the same as absorbing.
A peptide may dissolve successfully but still encounter barriers that prevent meaningful passage through the oral mucosa.
Some of the dose may also be swallowed.
Actual bioavailability must be measured rather than assumed.
Myth: Peptide troches work exactly like injections.
This is another misconception.
Different routes can produce substantially different absorption patterns, drug concentrations, and durations of exposure.
Without comparative pharmacokinetic and clinical evidence, the two routes should not be considered equivalent.
Myth: Smaller peptides are always absorbed effectively.
Molecular size is one factor influencing absorption, but it isn't the only one.
Charge, solubility, membrane permeability, stability, and formulation characteristics also matter.
A small peptide may still have poor absorption through oral tissues.
Myth: Compounded troches are automatically safer because they avoid needles.
Avoiding injections eliminates certain needle-related concerns, but it doesn't remove medication-related risks.
Troches may still produce systemic adverse effects, local irritation, inconsistent absorption, or interactions with other medications.
Compounded medications also have not undergone the same FDA premarket review as approved drug products.
The safety of a dosage form must be evaluated in the context of the specific medication and patient.
Why Working With a Compounding Pharmacist Matters
The growing interest in peptide therapy and personalized hormone replacement has created an enormous amount of information online.
Unfortunately, not all of it accurately represents pharmaceutical science.
Some discussions focus exclusively on injectable delivery, while others promote noninjectable formulations without adequately explaining their limitations.
At Restore Pharma, we believe patients and prescribers deserve a more thoughtful conversation.
As a 503A compounding pharmacy serving Tampa Bay and patients in other states where we're appropriately licensed, our role is to help healthcare providers evaluate medication needs and understand the pharmaceutical considerations associated with individualized preparations.
That includes discussing dosage forms, ingredient characteristics, formulation compatibility, and the limitations of available evidence.
It also means recognizing when a compounded preparation may not be the most appropriate option.
Compounding is not intended to replace suitable FDA-approved medications simply because a customized formulation is available.
Rather, it can serve patients who have legitimate clinical needs that available commercial products cannot adequately address.
For emerging peptide applications, additional regulatory and scientific questions must also be considered before any particular preparation can be offered.
The Future of Needle-Free Peptide Delivery
The field of peptide drug delivery continues to evolve.
Researchers are investigating technologies designed to improve the absorption of peptides and proteins through biological barriers.
These approaches include mucoadhesive delivery systems, specialized polymers, permeation enhancers, and other pharmaceutical strategies.
The goal is to make appropriate peptide-based medications more accessible and convenient without sacrificing safety or effectiveness.
Some of these technologies remain experimental, and successful laboratory findings do not always translate into practical clinical products.
Still, the research demonstrates why dismissing every noninjectable peptide formulation as ineffective is scientifically unjustified.
The more useful question is how researchers and pharmaceutical professionals can overcome the limitations associated with specific compounds.
As this field develops, well-designed pharmacokinetic studies and clinical trials will be essential to determining which noninjectable peptide formulations provide meaningful benefits.
Our Perspective at Restore Pharma
We understand why injectable peptides have become such a prominent part of the conversation.
For many compounds, injection offers a reliable way to bypass important absorption barriers.
But we also believe pharmaceutical innovation should include exploring appropriate alternatives.
Troches and other oral-mucosal dosage forms offer interesting possibilities, particularly for patients who prefer needle-free administration.
Their potential should neither be dismissed outright nor exaggerated.
The science tells us that sublingual and buccal delivery can work for certain medications, while peptide absorption presents challenges that require careful formulation and clinical evaluation.
For hormone replacement therapy, troches may have a role in selected individualized circumstances, although FDA-approved treatments should remain the preferred choice when suitable.
For peptides, the evidence must be evaluated compound by compound and formulation by formulation.
At Restore Pharma, we're passionate about the science of compounding and the possibilities of personalized pharmaceutical care.
Our boutique, concierge approach is built around collaboration with prescribers, accessibility to pharmacists, and helping patients understand their treatment options.
We don't believe every medication needs to be an injection.
We also don't believe every medication belongs in a troche.
We believe in understanding the science, respecting the evidence, and choosing the right approach for each patient's needs.
Because great pharmacy care isn't about following trends.
It's about helping patients make informed decisions.
Feel your best. Then feel better.
Patrick Alonso, PharmD, CPh
Steve Caddick, PharmD
Restore Pharma | Tampa Bay, Florida
Frequently Asked Questions About Troches and Sublingual Peptides
What is a medication troche?
A troche is a solid or semisolid dosage form designed to dissolve slowly in the mouth. Depending on the formulation, it may be placed under the tongue or against the inside of the cheek to allow potential absorption through the oral mucosa.
Are peptide troches effective?
Some peptides may be suitable for transmucosal delivery, but effectiveness depends on the specific compound and formulation. Research supports the scientific possibility of peptide absorption through oral tissues, although many peptides have poor permeability and limited clinical evidence supporting troche administration.
Are troches better than injections?
Neither route is universally better. Injections may provide more predictable delivery for certain medications, while troches may offer a convenient alternative when appropriate absorption and clinical effectiveness have been demonstrated.
Do sublingual peptides bypass the digestive system?
The portion of a medication absorbed directly through the oral mucosa can bypass initial gastrointestinal processing and hepatic first-pass metabolism. However, some of the dose may be swallowed, so this benefit is not necessarily complete.
Can troches be used for hormone replacement therapy?
Compounded troches have been used for certain hormone formulations, including estradiol, progesterone, and testosterone. However, absorption and clinical performance vary, and FDA-approved hormone therapies are generally preferred when appropriate.
Can peptide troches replace injectable peptides?
Not automatically. A peptide's effectiveness by injection does not establish equivalent absorption or clinical effects through a troche. Comparative studies are needed before assuming the routes are interchangeable.
Why does the troche formulation matter?
The base, dissolution characteristics, stability, and other formulation factors can influence how a medication is released and potentially absorbed. However, formulation quality alone does not guarantee adequate bioavailability or clinical effectiveness.
Can Restore Pharma help patients understand troche options?
Yes. Restore Pharma's pharmacists can help patients and prescribers understand dosage-form considerations, compounding requirements, and the available evidence. Whether a specific preparation is appropriate or legally available depends on the medication, prescription, and applicable regulations.
Educational Disclaimer: This article is intended for informational purposes only and does not constitute medical advice or a recommendation to use any particular compounded medication. Compounded medications are not FDA-approved, and the absorption, safety, and effectiveness of individual troche formulations may not be established through clinical trials. Patients should consult qualified healthcare professionals before beginning or changing hormone therapy or other medication regimens.
